OncoMatch/Clinical Trials/NCT03185468
Intervention of Bladder Cancer by CAR-T
Is NCT03185468 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies non-drug interventions for bladder cancer.
This is a Phase I/II and multicenter study designed to evaluate the efficacy and safety of 4SCAR-T cells in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have no further treatment available.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: any approved anti-cancer therapy
Cannot have received: investigational agent
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Adequate end organ function
Liver function
Adequate end organ function
Adequate hematologic and end organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03185468 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior any approved anti-cancer therapy, investigational agent disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages